Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Impact of new fatty liver disease nomenclature on primary care— cerebration of...
Journal Information
Share
Share
Download PDF
More article options
Letters to the editor
Full text access
Impact of new fatty liver disease nomenclature on primary care— cerebration of gastroenterologists in a regional tertiary care hospital
Visits
78
Xingcen Chena,b, Deliang Liua,b, Rong Lia,b,
Corresponding author
xylulr@csu.edu.cn

Corresponding author.
a Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China
b Research Center of Digestive Disease, Central South University, Changsha, China
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Dear Editor,

We read the study by Rinella et al. [1] with great interest, which is a significant advance in the liver disease research field. The authors proposed to use steatotic liver disease (SLD) recapitulating hepatic steatosis of various etiologies, metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD), and MetALD distinguishing MASLD patients who intake more alcohol (140 to 350 g/week and 210 to 420 g/week for females and males respectively). It will help hepatologists, clinicians, and patients better understand, manage, and treat diseases. Here, we pondered the impact of new fatty liver disease nomenclature on primary care /community health care.

First, long-term surveillance management of any chronic disease will fall to community health care. With the promotion of ultrasound in primary care, community clinicians can better identify MASLD and establish health records for residents. Adding “metabolic dysfunction” to disease nomenclature can make clinicians calmer when explaining the condition to patients and convince patients when doing health education to patients. For example, for nonalcoholic steatohepatitis (NASH) patients with a high risk of advanced fibrosis, guidelines recommend using pioglitazone, a thiazolidinedione, or vitamin E to improve liver pathology and cardiovascular metabolism[2,3]. Previously, clinicians had to explain to patients the rules and reasons for using such drugs, and this process was much easier after renaming. Before renaming, clinicians faced with NAFLD patients with alcohol consumption needed to make seemingly contradictory diagnoses of “NAFLD” and “alcohol-related liver disease (ALD).” At the same time, the newly added MetALD avoided this embarrassment.

Second, replacing the exclusive, stigmatized terms “nonalcoholic” and “fatty” with the positive, descriptive “metabolic dysfunction” and “steatosis” makes it more acceptable for patients, especially adolescent pediatric patients. More importantly, it is easier for patients to understand and accept health education about MASLD and work with clinicians to manage it.

However, it is arduous for a new name for a disease to be accepted by the public overnight, which requires community clinicians to study at top medical institutions in the region from time to time and pay real-time attention to the latest advances in medical knowledge. Due to habits, ongoing clinical trials, published document literature, and others, it may still take 5-10 years for MASLD to replace NAFLD completely.

Funding

This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Xingcen Chen: Writing – original draft, Writing – review & editing. Deliang Liu: Writing – original draft, Writing – review & editing. Rong Li: Writing – original draft, Writing – review & editing.

References
[1]
M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, et al.
A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
[2]
F. Kanwal, J.H. Shubrook, L.A. Adams, K. Pfotenhauer, V. Wai-Sun Wong, E. Wright, et al.
Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.
Gastroenterology, 161 (2021), pp. 1657-1669
[3]
K. Cusi, S. Isaacs, D. Barb, R. Basu, S. Caprio, W.T. Garvey, et al.
American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD).
Endocr Pract, 28 (2022), pp. 528-562
Copyright © 2024. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos